Comprehensive Analysis of Relapse in Multiple Sclerosis
Status:
Unknown status
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This study will determine changes in: 1) the immune activity, characterized as the
"immunorepertoire;" 2) 7 Tesla MRI brain images; 3) clinical outcomes; and 4) patient
reported quality of life outcomes in subjects with relapsing-remitting multiple sclerosis who
are treated with Acthar Gel.
Phase:
N/A
Details
Lead Sponsor:
Tanner Foundation for Multiple Sclerosis
Collaborators:
Auburn University MRI Research Center iReportoire Inc Mallinckrodt